Abstract: The present disclosure is related to a system for monitoring microcirculation is provided. The system may include a detector, the detector being inserted under a tongue of a user along a sagittal axis direction of the user; a light source, the light source being disposed on a surface of the detector in contact with a bottom surface of the tongue of the user and being configured to emit a light source signal to a target region under the tongue; and a lens set, the lens set being disposed within the detector for receiving a detection signal from the target region, wherein the detection signal is emitted into the detector along a vertical axis direction of the user and emitted out from the detector along the sagittal axis direction of the user.

Abstract: A discrimination device is a device that discriminates whether or not a discrimination target object is a blood cell based on an image of the discrimination target object, and includes a blood cell feature extraction unit that acquires an image of a blood cell and extracts a feature of the blood cell from the acquired image, a discrimination target object feature extraction unit that acquires the image of the discrimination target object and extracts a feature of the discrimination target object from the acquired image, and a discrimination unit that discriminates whether or not the discrimination target object is a blood cell through anomaly detection based on the extracted feature of the blood cell and the feature of the discrimination target object.

Abstract: Provided is a modified Fc region. The Fc region has at least one amino acid mutation with respect to a parent Fc region. The modified Fc region has improved affinity to Fc?RIIB with respect to the affinity of the parent Fc region to Fc?RIIB Also provided is an antibody containing the modified Fc region, especially an agonistic antibody. The modified Fc region has significant use for optimizing the agonistic activity of the antibody.

Abstract: A gradient mineralized cancellous bone matrix material and a preparation method thereof are provided, and the preparation method includes: processing naturally-derived bone tissue with an immunogenicity removal treatment for decellularization, and processing an obtained decellularzed bone with a gradient demineralization treatment to obtain the gradient mineralized cancellous bone matrix material. The present invention expands a porosity of the bone matrix material and a collagen exposure degree on a surface thereof, which effectively releases growth factors and improves adhesion of the material to the cells, so as to up-regulate genes and proteins related to cell regeneration.

Abstract: A composition of drug targets and the use the method of using thereof. The composition comprises a vector and a drug using FKBP10 and PCOLCE genes and/or the encoded proteins thereof as drug targets.

Abstract: The present invention provides an application of thyroid hormones and thyroid hormone analogues to preparation of drugs for treating sickle-cell disease, particularly an application to preparation of drugs for improving the expression quantity of ?-globin. During the differentiation of K562 cells, thyroid hormone analogue (Triac) can significantly up-regulate the expression of ?globin gene (HBZ) by 50 folds or above. The expression of -globin gene (hbae5) can also be up-regulated by 30-70 folds in zebrafish treated with thyroid hormones and thyroid hormone analogues. Therefore, according to the present invention, the expression of -globin gene can be significantly activated by thyroid hormones and thyroid hormone analogues which may develop new potential therapies for patients with sickle-cell disease. It provides an economical, safe and effective method for treating sickle-cell disease and can be widely used.

Abstract: The present invention provides a method and system for diagnosing a central nervous system disease, and a composition, and a kit. The diagnosing system comprises: a first detection module, used for detecting a central nervous system-derived marker in a biological body fluid of a subject; a second detection module, used for detecting a central nervous system disease-related marker in the biological body fluid of the subject; and a diagnosis module, diagnosing, on the basis of central nervous system-derived marker and central nervous system disease-related marker detection results respectively obtained by the first detection module and the second detection module, whether the subject suffers from a central nervous system disease.

Abstract: An interference image acquisition apparatus includes a light source, a beam splitter, a second reflection mirror, an imager, and a first reflection mirror. A cell is placed on one side of a transparent material, and the first reflection mirror is placed on the other side of the transparent material. In a two-beam interferometer, an optical path difference between an optical path length of a first light beam reflected by the first reflection mirror and an optical path length of a second light beam reflected by the second reflection mirror is set to a coherence length of light output from the light source or less. The imager acquires an interference image in a state in which the cell is placed at a position conjugate to an imaging plane in a first optical system between the imaging plane and the first reflection mirror.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: Provided is a non-invasive and prompt testing method, in which a mucus adhering onto the surface of a mucous membrane is used as a specimen. A method for collecting a specimen by wiping out a mucus adhering onto the surface of a mucous membrane, when the specimen is collected during an endoscopic examination.

Abstract: The present disclosure relates to a difficult airway evaluation method and device based on a machine learning voice technology. The method includes the following steps: acquiring voice data of a patient; carrying out feature extraction on the voice data, obtaining a pitch period of pronunciations, and acquiring a voiced sound feature and unvoiced sound features based on the pitch period of pronunciations; and constructing a difficult airway evaluation classifier based on the machine learning voice technology, analyzing the received voiced sound feature and unvoiced sound features by the trained difficult airway evaluation classifier, and carrying out scoring on the severity of a difficult airway to obtain an evaluation result of the difficult airway.

Abstract: The present disclosure provides methods and kits for diagnosing and assessing SAGE1-positive disorders, and compositions and methods for treating SAGE1-positive disorders. The present disclosure further provides SAGE1 complexes and methods and composition for inhibiting SAGE1 complexes and treating SAGE1-positive disorders.

Abstract: The present application provides an automatic knife stop device and a system for fibula cutting, a computer equipment, and a medium. The device includes: an acquisition module; a threshold module; and a judgment module. The present application can avoid the destruction of blood vessels during shaping and greatly improve the success rate of surgery, while greatly improve the robustness of the control system by increasing the strength of the force feedback signal.

Abstract: The present application provides an automatic knife stop device and a system for fibula cutting, a computer equipment, and a medium. The device includes: an acquisition module; a threshold module; and a judgment module. The present application can avoid the destruction of blood vessels during shaping and greatly improve the success rate of surgery, while greatly improve the robustness of the control system by increasing the strength of the force feedback signal.

Abstract: Use of glycerol in preparing an adipose tissue cryopreservation protective agent and the adipose tissue cryopreservation protective agent. Based on the total volume of the adipose tissue cryopreservation protective agent, the adipose tissue cryopreservation protective agent includes: glycerol with a volume fraction of 60-80%; 0.090-0.200 g/ml trehalose; and a PBS buffer serving as the solvent. The adipose tissue cryopreservation protective agent is free of DMSO and other protective agents having biological toxicity, poses no toxicity to cells and tissues, and causes no safety problem during clinical use even in a case of incomplete elution. The adipose tissue cryopreservation protective agent is free of xenoantigen and has low cost. With glycerol and trehalose being clinically approved medicinal ingredients and inexpensive products, the agent of the present disclosure contains no costly products such as human albumin, thus providing increased possibility for clinical use and promotion.

Abstract: The present disclosure provides the use of a recombinant human secretory DDRGK1. Experiments demonstrate that the recombinant human secretory DDRGK1 prepared by the present disclosure can be used in the preparation of biological medicines for treating intervertebral disc degeneration, fractures or bone defects. The recombinant human secretory DDRGK1 of the present disclosure provides a promising direction for the treatment of bone related diseases and has obtained firm scientific evidence, thereby expanding the further application of recombinant human secretory DDRGK1 in clinical practice.

Abstract: A method for detecting tumor tissue boundaries or a tumor stromal cell distribution range, more specifically, a diagnostic or non-diagnostic method for determining the boundaries of a tumor tissue; the boundaries of the tumor tissue are determined by means of determining the boundaries of the tumor stromal cells in the tumor tissue. The present method can more accurately determine the boundaries of tumor tissue, which serves to more accurately instruct the treatment of tumors, especially with respect to surgical treatment.

Abstract: A method for determining a prognosis of idiopathic pulmonary fibrosis, comprising the following steps (a) to (c): (a) a step of detecting an amount of at least one protein selected from S100A4, CIRP, and 14-3-3? for a biological sample separated from the test subject; (b) a step of comparing the amount of the protein detected in the step (a) with a standard amount of the protein; and (c) a step of determining that the prognosis of idiopathic pulmonary fibrosis of the test subject is poor in a case where as a result of the comparison in the step (b), the amount of the protein in the test subject is higher than the standard amount.

Abstract: An injectable in situ pore-forming hydrogel system and its preparation method and use are provided. The injectable in situ pore-forming hydrogel system uses an injectable hydrogel as a continuous base phase, and isolated live cells and magnesium particles are distributed in the continuous base phase, where the injectable hydrogel is a precursor or prepolymer of hydrogel, which can form hydrogel by cross-linking. The injectable in situ pore-forming hydrogel system can be used to create pores while the gel encapsulates live cells, which makes use of both the injectability and porous structures of hydrogel, which is important for the repair of cavitary, surgically difficult and irregularly defective tissues; meanwhile, magnesium particles generate magnesium ions after the former undergoes gas production and degradation, which can improve the bioactivity of the gel and aid in tissue repair.

Abstract: The present disclosure relates to the field of medicines, in particular to the use of IGSF10 in the preparation of a bone tissue regeneration product, especially the use of IGSF10 in combination with BMP in the preparation of a product for promoting bone tissue regeneration. The product includes a periodontal bone defect repair product, a jaw bone defect repair product and/or a skull defect repair product. The new use of IGSF10 of the present disclosure can reduce the effective concentration of BMP without obvious adverse reactions, thereby exploring a method to promote bone tissue regeneration and providing new ideas for the treatment of bone defects.